"Helius: Healing or High-Flying Hype?"Medical miracles or speculative spectacle? Helius is low-priced but high in surprises. A single FDA nod could send shorts running for the exits, not knowing what arises!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−6.1786 USD
−8.85 M USD
644.00 K USD
3.68 M
About Helius Medical Technologies, Inc.
Sector
Industry
CEO
Dane Carl Andreeff
Website
Headquarters
Newtown
Founded
2014
FIGI
BBG006QSQYY6
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.
$HSDT Next Target PTs 2.25-2.75 and higherHelius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device in
short term +800%Helius Medical Technologies, Inc., is a neurotech company in the medical device industry, focused on neurological wellness.
HSDT Trending UPStrong Patterns are in Play ...
* Adam & Eve
* Cypher
* Double Bottom
Short & Long-term targets marked.
Good spread between price and Weekly 200MA.
Do ur own DD and EES;)
Reverse head and shoulders, bullishSpotted a reverse head and shoulders, confirmation above the 20 EMA line. Might go for for a run, keep an eye out on this.
- Expecting consolidation at 0.48, needs to pass 0.55 for a breakout a 0.55
- Stop loss at 0.45
This is just an idea, do your own DD and good luck
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of HSDT is 0.6639 USD — it has decreased by −13.56% in the past 24 hours. Watch Helius Medical Technologies, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Helius Medical Technologies, Inc. stocks are traded under the ticker HSDT.
HSDT stock has fallen by −32.02% compared to the previous week, the month change is a 53.89% rise, over the last year Helius Medical Technologies, Inc. has showed a −91.63% decrease.
HSDT reached its all-time high on Oct 11, 2017 with the price of 36,225.0000 USD, and its all-time low was 0.3730 USD and was reached on Oct 15, 2024. View more price dynamics on HSDT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
HSDT stock is 12.34% volatile and has beta coefficient of −2.37. Track Helius Medical Technologies, Inc. stock price on the chart and check out the list of the most volatile stocks — is Helius Medical Technologies, Inc. there?
Today Helius Medical Technologies, Inc. has the market capitalization of 2.61 M, it has increased by 109.27% over the last week.
Yes, you can track Helius Medical Technologies, Inc. financials in yearly and quarterly reports right on TradingView.
Helius Medical Technologies, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
HSDT earnings for the last quarter are −0.99 USD per share, whereas the estimation was −1.06 USD resulting in a 6.60% surprise. The estimated earnings for the next quarter are −0.94 USD per share. See more details about Helius Medical Technologies, Inc. earnings.
Helius Medical Technologies, Inc. revenue for the last quarter amounts to 51.00 K USD, despite the estimated figure of 150.00 K USD. In the next quarter, revenue is expected to reach 100.00 K USD.
HSDT net income for the last quarter is −3.69 M USD, while the quarter before that showed −1.61 M USD of net income which accounts for −128.66% change. Track more Helius Medical Technologies, Inc. financial stats to get the full picture.
No, HSDT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 22.00 employees. See our rating of the largest employees — is Helius Medical Technologies, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Helius Medical Technologies, Inc. EBITDA is −12.93 M USD, and current EBITDA margin is −1.88 K%. See more stats in Helius Medical Technologies, Inc. financial statements.
Like other stocks, HSDT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Helius Medical Technologies, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Helius Medical Technologies, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Helius Medical Technologies, Inc. stock shows the sell signal. See more of Helius Medical Technologies, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.